Burch, Jane and Magalhães, Pedro V (2017) Clinical question: How do alpha2‐adrenergic agonists compare with placebo or methadone for management of opioid withdrawal? Cochrane Clinical Answers,
External website: https://www.cochranelibrary.com/cca/doi/10.1002/cc...
Alpha2‐adrenergic agonists may be beneficial for controlling symptoms of opioid withdrawal. However, when compared with reduced doses of methadone, retention may be worse and risk of adverse events greater with alpha2‐adrenergic agonists....
B Substances > Opioids (opiates) > Opioid product
B Substances > Opioids (opiates) > Opioid product > Methadone
G Health and disease > Substance use disorder (addiction) > Drug use disorder > Drug withdrawal / craving
HJ Treatment or recovery method > Substance disorder treatment method
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Treatment outcome
J Health care, prevention, harm reduction and treatment > Patient / client care management
N Communication, information and education > Recommendations > Practice / clinical guidelines
VA Geographic area > International
Repository Staff Only: item control page